BIP Capital Partners

Skip to content

HOME
About us
- OUR TEAM
- OUR HISTORY
investment approach
- INVESTMENT APPROACH
- INVESTMENT CHARACTERISTICS
portfolio
- SELECTED INVESTMENTS
- SELECTED EXITS
News
CONTACT

Enzymotec reports 4th quarter and full year 2014 unaudited financial results

Post navigation

Previous PostLSP, one of BIP’s fund investments, has announced that its portfolio company Prosensa N.V. received tender offer from Biomarin Next PostEnzymotec reports second quarter 2015 results

© BIP Group Luxembourg 2024

Stay in touch with us, leave your email